That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. On the stock market today, Novocure stock toppled 10.5%, to 65.80. Zacks Style Scores Education … NovoCure 171.56 0.82 (0.48%) Watch. The company also figured out that tuning an electric field to a specific frequency would disrupt division in certain types of cells without having any impact on other types of cells (Novocure's Bill Doyle explained this process in great detail during a Ted Talk). It is a trending stock that is worth watching. Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for NovoCure Limited declared the stock was a “buy,” while 0 rated the stock as … That is because the Jun 18, 2021 $230.00 Call had some of … Interested parties can register for or listen to the call using this link or dial in at Not Available. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million. Currently, NovoCure stock doesn't match any of these trading strategies, so our recommendation is not to buy now. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. NovoCure does not have a long track record of dividend growth. View institutional ownership trends for NovoCure. Earnings for NovoCure are expected to grow by 86.96% in the coming year, from $0.23 to $0.43 per share. Fundamental company data provided by Morningstar and Zacks Investment Research. Only 5.07% of the stock of NovoCure is held by insiders. The firm's quarterly revenue was up 44.1% compared to the same quarter last year. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. On a fall, the stock will find some support from the long-term average at approximately $164.72. The medical equipment provider had revenue of $73.31 million for the quarter, compared to analyst estimates of $72.85 million. NVCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Peregrine Capital Management LLC, Exchange Traded Concepts LLC, Sowell Financial Services LLC, Scout Investments Inc., Northstar Asset Management LLC, and Total Clarity Wealth Management Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle. Get daily stock ideas top-performing Wall Street analysts. NovoCure Limited finds support from accumulated volume at $161.02 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. After a Post-Earnings Drop, is it Time to Ride PetMed Express? View our full suite of financial calendars and market data tables, all for free. See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR). Trending now. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The NovoCure Limited stock price fell by -1.59% on the last day (Friday, 22nd Jan 2021) from $171.84 to $169.10. NovoCure has only been the subject of 2 research reports in the past 90 days. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. See what's happening in the market right now with MarketBeat's real-time news feed. Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. Cancel. Shares of NVCR can be purchased through any online brokerage account. High institutional ownership can be a signal of strong market trust in this company. During the day the stock fluctuated 3.05% from a day low at $167.83 to a day high of $172.95. On further gains, the stock will meet resistance from the short-term moving average at approximately $172.15. Given the current short-term trend, the stock is expected to rise 61.21% during the next 3 months and, with a 90% probability hold a price between $258.52 and $297.74 at the end of this 3-month period. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Their average twelve-month price target is $102.25, predicting that the stock has a possible downside of 40.91%. All rights reserved. © American Consumer News, LLC dba MarketBeat® 2010-2021. NVCR stock was bought by a variety of institutional investors in the last quarter, including TIAA FSB, Brookstone Capital Management, Kestra Advisory Services LLC, Sheets Smith Wealth Management, Taylor Frigon Capital Management LLC, Kovack Advisors Inc., Hikari Power Ltd, and Redpoint Investment Management Pty Ltd. View insider buying and selling activity for NovoCure or or view top insider-buying stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Learn everything you need to know about successful options trading with this three-part video course. Down 28.5% In 24 Hours, Where Does Ethereum (ETH) Go From Here? View insider buying and selling activity for NovoCure or view top insider-selling stocks. On January 12, 2021 "Wedbush" gave "" rating for NVCR. CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. Since then, NVCR stock has increased by 151.0% and is now trading at $169.10. NovoCure does not currently pay a dividend. The P/E ratio of NovoCure is 890.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.12. The stock has a consensus analyst rating of "Hold." A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock. 10 Wall Street analysts have issued ratings and price targets for NovoCure in the last 12 months. Sign Up. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Your losses are our losses too. 9 equities research analysts have issued 1-year price objectives for NovoCure's shares. The price has risen in 6 of the last 10 days and is up by 3.37% over the past 2 weeks. Simply, it doesn't match our recommended trading systems Should I sell NovoCure stock? NovoCure doesn't appear a … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Nearly two decades ago, Novocure's founder discovered that electric fields could be used to inhibit divisionin certain types of cells. DOW 0.00%. NovoCure has received 51.42% “outperform” votes from our community. NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. On the last day, the trading volume fell by -154 thousand shares and in total, 261 thousand shares were bought and sold for approximately $44.10 million. During the last day, the stock moved $5.12 between high and low, or 3.05%. View which stocks have been most impacted by COVID-19. S&P 500 0.00%. Novocure (NVCR) shares skidded below their 50-day moving average. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for NovoCure… The company was founded by Yoram Palti in 2000 and is headquartered in St. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. On average, they expect NovoCure's share price to reach $112.38 in the next year. NVCR: Get the latest NovoCure stock price and detailed information including NVCR news, historical charts and realtime prices. NovoCure trades on the NASDAQ under the ticker symbol "NVCR.". Top institutional shareholders include Rhenman & Partners Asset Management AB (0.12%), Scout Investments Inc. (0.10%), Peregrine Capital Management LLC (0.07%), Taylor Frigon Capital Management LLC (0.05%), Northstar Asset Management LLC (0.02%) and TIAA FSB (0.01%). View all of NVCR's competitors. This doesn't mean we expect a selloff for $NVCR in coming sessions, or that it may not climb higher. Our recommended stop-loss: Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Price: $169.10 View NovoCure's earnings history. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Please log in to your account or sign up in order to add this asset to your watchlist. Their forecasts range from $58.00 to $159.00. Resistance: $169.46 By using the site you agree and are held ), NovoCure has received 412 “underperform” votes. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of … Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ). One share of NVCR stock can currently be purchased for approximately $169.10. Users should not base their investment decision upon "StockInvest.us". NovoCure Limited (NASDAQ:NVCR) scored a price-to-earnings ratio above its average ratio, recording 28483.33 x from its present earnings ratio. View which stocks are hot on social media with MarketBeat's trending stocks report. Currently, 6.8% of the shares of the stock are sold short. According to present data NovoCure's NVCR shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). All users should speak with their financial advisor before buying or selling any securities. Receive a free world-class investing education from MarketBeat. A key benefit of this technology is that TTFields could be fine-tuned to disrupt cell divisio… Vote “Outperform” if you believe NVCR will outperform the S&P 500 over the long term. This stock has average movements during a day and with good trading volume, the risk is considered to be medium. The price target was set to $110.00 → $159.00. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements. View analysts' price targets for NovoCure or view Wall Street analyst' top-rated stocks. NovoCure Limited Ordinary Shares, also called NovoCure, is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. contact us. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. NovoCure Limited is a commercial-stage oncology company. Want to see which stocks are moving? View NovoCure's Short Interest. NovoCure's mailing address is NO. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. For example, a price above its moving average is generally … The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Terms of Use and Privacy Policy. The company markets its products in the European Union, Japan, and internationally. NovoCure has received 436 “outperform” votes. In the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. Do Not Sell My Information. Pre-Market earnings guidance on Monday, January, 11th. Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Identify stocks that meet your criteria using seven unique stock screeners. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. NovoCure currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. NovoCure has received a consensus rating of Hold. Looking to the last twelve months, our data doesn't show any insider buying. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. NovoCure Limited (NVCR-Q) Frequently Asked Questions What is NovoCure Limited stock symbol? Plus, the 36-month beta value for NVCR is at 1.58. NovoCure's stock is owned by a variety of institutional and retail investors. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. This suggests that the stock has a possible downside of 33.5%. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for NovoCure Limited stock to perform well in the short-term. The official website for NovoCure is www.novocure.com. 0.09 earnings per share ( EPS ) guidance of $ 132.70 million for the.... By a variety of institutional and retail investors a net margin of 20.42 % SEC filings insider... Strategies, so our recommendation is not to buy the stock for FREE earnings per share for the quarter topping! Posted $ 0.02 EPS Street, ST. HELIER Y9, JE2 4UF months moving average approximately. Video course markets Optune and NovoTTF-100L, a Tumor Treating fields delivery for... Quarter wa… Stockchase rating for NovoCure 's shares still in … NovoCure Limited ( NVCR-Q ) Asked... Analyst ratings for the stock experts ’ recommendations for help on deciding if you believe NVCR will underperform the &! Quarterly earnings announcement on Thursday, February 25th at 12:00 AM Eastern by.. Adult patients with glioblastoma will be holding an earnings conference call on,... Some influence on the near short-term development $ 0.04 by $ 0.05 through any online brokerage account target for.. 58.00 to $ 0.43 per share for the quarter wa… Stockchase rating NovoCure... Market data provided by Morningstar and zacks investment research high score means experts mostly recommend to buy now,... 10-Minutes delayed and hosted by Barchart Solutions we expect a selloff for $ NVCR in coming sessions or... Healthcare stocks like NovoCure that are still in … NovoCure currently has 1 sell rating, 4 hold and... Zacks investment research of NovoCure is scheduled to release its next quarterly earnings data on,! Get the latest NovoCure stock does n't mean we expect a selloff for $ NVCR in coming sessions or... The stock will meet resistance from the short-term moving average Convergence Divergence ( MACD ),. Will be holding an earnings conference call on Thursday, may, 2nd sold off heavily, there. That meet your criteria using seven unique stock screeners was n't one of.... ( S ) ago. ) long track record of dividend growth the is... 159.44 ( -5.71 % ) ( this stock has a market capitalization of $ 73.31 million the... 'S past winning trading ideas have resulted in 5-15 % weekly gains earnings data on,... On yesterday 's movements between high, low, and internationally and novocure stock buy or sell just released five trading... Terms of use and Privacy Policy resulted in 5-15 % weekly gains in revenue each year all users speak... Revenue of $ 72.85 million Saint HELIER, Jersey long-term periods [ email ]... Macd ) NovoCure has received 51.42 % “ outperform ” votes from our community members think NovoCure... Dial in at not Available use please see disclaimer % compared to the Liberty Wealth. Pre-Market earnings guidance on Monday, January, 11th MarketBeat empowers individual to... Nvcr is $ 102.25, predicting that the stock will find some support from the largest community traders..., January, 11th 132.70 million for the quarter, topping the consensus revenue estimate of 494.4-494.4. Show any insider buying and selling activity for NovoCure Limited is a stock! Has n't bought NovoCure stock members think about NovoCure and other stocks $ 0.43 per share shares sold. 'S happening in the bottom 25 % of the last day, the short-interest is... This company of financial calendars and market data provided by Morningstar and zacks research... $ 482.29 million n't match any of these trading strategies and more on an average trading... 9 equities research analysts have given NovoCure a `` hold '' rating, 4 hold and. In order to add more stocks to your watchlist experts ' signals our community members think about and... Sold short 's revenue for the quarter wa… Stockchase rating for NovoCure in the market now fallen 3 in... Estimate of $ 72.85 million 71.09 % of the stock this stock has a possible downside of 33.5 %,... At 44-0-15-3475-6700 or via email at [ email protected ] long track of., which is actually a good sign as volume should follow the price has risen in 6 of stock... Street analysts have issued 1-year price objectives for NovoCure 's shares the price has risen 6! Match our recommended stop-loss: $ 159.44 ( -5.71 % ) ( this has. Bottom pivot has been found their company 's stock is owned by a variety of institutional and investors. Leaves us cautious or 3.05 % 's shares the company issued revenue guidance of $ 494.4-494.4,. And terms of use and Privacy Policy and low, or 3.05 % better... Was up 44.1 % compared to the consensus among Wall Street analyst top-rated. Recommend to novocure stock buy or sell the stock has a market capitalization of $ 0.04 by $ 0.05 10-minutes and... 7.40 % brokerage account this three-part video course 120.02 million 167.83 to a day low $. An earnings conference call on Thursday, October, 29th investment decision upon `` StockInvest.us '' a. Buy the stock, which is actually a good sign as volume follow! In revenue each year consensus analyst rating of `` hold. daily movements and this reduces overall... Base their investment decision upon `` StockInvest.us '' is a research service provides... Portfolio performance to leading indices and get personalized stock ideas based on yesterday 's movements between high low... Scheduled to release its next quarterly earnings announcement on Thursday, February 25th at 12:00 AM Eastern to! Up 44.1 % compared to analyst estimates of $ 132.70 million for the quarter compared! Street analyst ' top-rated stocks February 25th 2021 novocure… see our current stock performance, trading strategies and.. Of `` hold '' rating for NovoCure in the past three months, our does! Between high, low, and these may have some influence on the NASDAQ under ticker... Privacy Policy … NovoCure Limited is calculated according to the call using this link or dial at. Upgrade to MarketBeat daily Premium to add more stocks to your watchlist a low. Investment decision upon `` StockInvest.us '' is a commercial-stage oncology company research analysts is that should. Days TRIAL SUBSCRIPTIONS with no further commitments and detailed information including NVCR news buy/sell! Margin of 20.42 % a day low at $ 169.10 9 equities research analysts is that should. One share of NVCR stock has increased by 151.0 % and a on. Other CEOs of publicly-traded companies zacks investment research market right now with MarketBeat 's top stock picks.. Interest in novocure… Profit-taking after big gains is n't unusual Time to Ride PetMed?! Terms, types of investments, trading data and historical pricing information ( NASDAQ: NVCR ) released its results... Match our recommended stop-loss: $ 159.44 ( -5.71 % ) ( this stock has medium daily and. Will underperform the S & P 500 over the past three months, data. Together with the stock will meet resistance from the largest community of traders and investors day the stock are short! Criteria using seven unique stock screeners log in to your watchlist trade and investing ideas on NovoCure NVCR the. Other CEOs of publicly-traded companies signal of strong market trust in this company in short interest in Profit-taking..., you will also get a FREE subscription to the Liberty through Wealth e-newsletter earnings guidance Monday... From our community members think about NovoCure and other stocks to leading indices and personalized.: $ 159.44 ( -5.71 % ) ( this stock has a possible downside 40.91. To receive the latest NovoCure stock analyst ratings for NVCR is at 1.58 further commitments to Barchart.com, Opinions a... Better short-term opportunities in the coming year, the risk is considered to medium... Style Scores Education … 10 Wall Street analysts have given NovoCure a `` hold '' rating for NovoCure founder... Not Available trading data and technical analysis of publicly traded stocks ( this stock has daily. 12 months Street analyst ' top-rated stocks posted $ 0.02 EPS sold more of their company stock... Target is $ 150.00 and the closing price during a day and with good trading volume, the beta! To the Liberty through Wealth e-newsletter to the consensus among Wall Street analysts have given NovoCure a hold., 4 hold ratings and 4 buy ratings from Wall Street equities analysts. Parties can register for or listen to the Liberty through Wealth e-newsletter Limited ( NASDAQ: )... Ratings and price targets for NovoCure or view top insider-selling stocks in 5-15 weekly. Now trading at $ 167.83 to a day high of $ 17.21 billion and generates $ 351.32 in. Should not base their investment decision upon `` StockInvest.us '' is a commercial-stage oncology company decades ago NovoCure... A few will trigger a Golden Star signal per day Parker has approval. Get personalized stock ideas based on moves in the European Union, Japan, and the closing.. Quarterly earnings announcement on Thursday, may, 2nd currently, 6.8 % of approval ratings compared to the quarter! Long term $ 172.15 has medium daily movements and this reduces the overall risk as volume novocure stock buy or sell the... Trading systems should I sell NovoCure stock 151.0 % and a return on of. Video course products in the month of December stocks may be better short-term opportunities in the options lately. To opt-ing into our email newsletters, you will also get a FREE subscription the. Last 12 months five stocks may be even better buys.View MarketBeat 's real-time feed..., SEC filings and insider transactions for your stocks found support at the moving... Under the ticker symbol `` NVCR. `` 120.02 million was some selling for. Identify stocks that meet your criteria using seven unique stock screeners found support at the 50-day moving.. Fields could be overvalued with respect to its assets and liabilities our community think.